Disparities in the use of antineoplastic immunotherapy in pediatric malignant adrenal tumors.

Autor: Shoag JM; Department of Pediatric Hematology and Oncology, University of Miami School of Medicine, Miami, Florida.; Jackson Memorial Hospital, Miami, Florida., Podda A; Department of Pediatric Hematology and Oncology, University of Miami School of Medicine, Miami, Florida.; Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, Florida., Kobetz EN; Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, Florida.
Jazyk: angličtina
Zdroj: Pediatric blood & cancer [Pediatr Blood Cancer] 2020 Sep; Vol. 67 (9), pp. e28522. Date of Electronic Publication: 2020 Jul 02.
DOI: 10.1002/pbc.28522
Abstrakt: Dinutuximab is a costly life-prolonging immunotherapy for high-risk neuroblastoma. We used a large pediatric inpatient database to analyze the use of antineoplastic immunotherapy in patients with malignant adrenal tumors 1 year after Food and Drug Administration approval of dinutuximab for high-risk neuroblastoma. On multivariate modeling, children of Black race (odds ratio [OR] 0.62, P = .04; referent non-Black) and the lowest ZIP code income quartile (OR 0.74, P = .03; referent wealthier 3 quartiles) were significantly less like to receive antineoplastic immunotherapy. These results suggest substantial disparities in the distribution of a vital therapy in children with advanced cancer.
(© 2020 Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz: